SB-332235 is primarily recognized for its role in scientific research, particularly in the study of inflammation and immune responses. It functions as a potent and selective antagonist of the CXCR2 receptor, which is involved in mediating neutrophil migration and activation. By inhibiting CXCR2, SB-332235 has been used in experimental models to investigate its potential in reducing inflammation associated with conditions such as chronic obstructive pulmonary disease (COPD), asthma, and arthritis. Its application in preclinical studies has provided valuable insights into the mechanisms of inflammatory diseases and the potential therapeutic benefits of targeting the CXCR2 pathway.